Allergan celebrates commitment to KSA with new entity inaugural
Allergan PLC ( Allergan), a global pharmaceutical company, in collaboration with Cigalah Group, a leader in pharmaceutical business in Saudi Arabia, celebrated the inauguration of their newly established entity Allergan Saudi LLC recently.
About 150 dignitaries and representatives from health care authorities and governmental officials attended the event.
Ismail Bakr, country manager of Allergan Saudi LLC, said: “We are very proud of the new presence of Allergan in the Kingdom. Our expansion, announced today is testimony to our commitment to health care professionals and their patients within the country.”
He added: “Allergan Saudi LLC is a multi-specialty health care company focused on developing and commercializing innovative branded pharmaceuticals, devices and biological products. Allergan is committed to working with phy- sicians, health care providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.”
Allergan’s strategic vision is in alignment with the Kingdom’s Vision 2030 initiated by King Salman and Deputy Crown Prince Mohammed bin Salman. Vision 2030 was established to encourage foreign investments particularly for multinational companies such as Allergan. With Allergan’s commitment to medical education and major knowledge-based contributions in the medical sector, Saudi Arabia can expect to generate inspiring outcomes in the near future.
Allergan PLC (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model — Growth Pharma. Allergan markets a portfolio of best-in-class products for eye care, medical aesthetics and dermatology, gastroenterology, central nervous system, urology and anti-infective therapeutic categories and women’s health. With commercial operations in about 100 countries, Allergan’s success is powered by more than its 16,000 employees.